Who are the Institutional Holders in CRISPR Therapeutics AG (CRSP)?

CRISPR Therapeutics AG (NASDAQ: CRSP) is 9.95% higher on its value in year-to-date trading and has touched a low of $37.55 and a high of $76.97 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CRSP stock was last observed hovering at around $65.72 in the last trading session, with the day’s gains setting it 3.11%.

Currently trading at $68.83, the stock is 7.73% and 6.73% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.97 million and changing 4.73% at the moment leaves the stock 22.58% off its SMA200. CRSP registered 24.00% gain for a year compared to 6-month gain of 29.75%. The firm has a 50-day simple moving average (SMA 50) of $23.35 and a 200-day simple moving average (SMA200) of -$9.85.

Invest Like Buffett: Travel Back in Time & Grab This High-Potential Stock Before It Explodes

Imagine buying Apple for $1, Amazon for $2, or Tesla for $3. Now, imagine the same opportunity with a hidden gem trading under $3 right now.

Our premium newsletter, powered by AI and expert analysis, uncovers these time-travel investment opportunities.

Invest like Buffett and profit from undervalued gems before the market catches on.

Limited-time offer: Get your first month for just $2.90 and start your journey to wealth creation.


The stock witnessed a 9.90% loss in the last 1 month and extending the period to 3 months gives it a 17.50%, and is 6.43% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.89% over the week and 4.90% over the month.

CRISPR Therapeutics AG (CRSP) has around 458 employees, a market worth around $5.47B and $170.01M in sales. Profit margin for the company is -207.95%. Distance from 52-week low is 83.30% and -10.58% from its 52-week high. The company has generated returns on investments over the last 12 months (-18.09%).

CRISPR Therapeutics AG quarterly earnings per share for the current quarter are estimated at $0.04 with sales reaching $151.63M over the same period.The EPS is expected to grow by 66.11% this year, but quarterly earnings will post 26,005.20% year-over-year. Quarterly sales are estimated to grow 2,527,066.80% in year-over-year returns.

578 institutions hold shares in CRISPR Therapeutics AG (CRSP), with institutional investors hold 69.12% of the company’s shares. The shares outstanding are 78.51M, and float is at 76.10M with Short Float at 22.39%. Institutions hold 68.15% of the Float.

The top institutional shareholder in the company is ARK Investment Management, LLC with over 7.16 million shares valued at $325.13 million. The investor’s holdings represent 9.02% of the CRSP Shares outstanding. As of Jun 29, 2023, the second largest holder is Capital International Investors with 6.07 million shares valued at $340.75 million to account for 7.64% of the shares outstanding. The other top investors are T. Rowe Price Investment Management, Inc. which holds 3.65 million shares representing 4.59% and valued at over $204.72 million, while Nikko Asset Management Americas, Inc. holds 4.45% of the shares totaling 3.53 million with a market value of $198.36 million.

CRISPR Therapeutics AG (CRSP) Insider Activity

A total of 0 insider transactions have happened at CRISPR Therapeutics AG (CRSP) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Kulkarni Samarth, the company’s Chief Executive Officer. SEC filings show that Kulkarni Samarth sold 50,000 shares of the company’s common stock on Jan 29 at a price of $60.51 per share for a total of $3.03 million. Following the sale, the insider now owns 0.19 million shares.

CRISPR Therapeutics AG disclosed in a document filed with the SEC on Jan 16 that Kulkarni Samarth (Chief Executive Officer) sold a total of 20,000 shares of the company’s common stock. The trade occurred on Jan 16 and was made at $62.50 per share for $1.25 million. Following the transaction, the insider now directly holds 0.19 million shares of the CRSP stock.

Still, SEC filings show that on May 30, Kulkarni Samarth (Chief Executive Officer) disposed off 25,000 shares at an average price of $64.88 for $1.62 million. The insider now directly holds 387,377 shares of CRISPR Therapeutics AG (CRSP).

CRISPR Therapeutics AG (CRSP): Who are the competitors?

One of the company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading -90.24% down over the past 12 months.Plandai Biotechnology Inc. (PLPL) lies in the list of competitors of the CRISPR Therapeutics AG and is -33.33% lower over the same period from CRSP